Abstract:Nonalcoholic fatty liver disease (NAFLD) is strongly associated with hepatic insulin resistance (HIR), however the key lipid species and molecular mechanisms linking these conditions are widely debated. In order to address these questions, we examined the metabolic impact of a liver-specific antisense oligonucleotide against PKCe and found that liver-specific PKCe knockdown ameliorated high-fat diet-induced HIR in rats, reflected by ∼2x increase in insulin-stimulated hepatic glycogen synthesis rate and improved insulin-mediated suppression of endogenous glucose production during a hyperinsulinemic-hyperglycemic (HH) clamp. This was associated with increased IRK Y1162 and Akt S473 phosphorylation and could be attributed to decreased PKCe-mediated IRK T1160 phosphorylation. Overexpressing a constitutively active PKCe (A159E) in the liver induced HIR in regular chow-fed rats, reflected by reduced insulin-stimulated glycogen synthesis rate during an HH clamp. This was associated with impaired IRK Y1162 and Akt S473 phosphorylation and could be attributed to increased PKCe-mediated IRK T1160 phosphorylation. We also developed a subcellular fractionation method to quantify diacylglycerol (DAG) stereoisomers and ceramides in the endoplasmic reticulum, mitochondria, plasma membrane (PM), lipid droplet and cytosol and applied this method to a cohort of obese human subjects with and without NAFLD and HIR. Liver PM sn-1,2 DAG content was ∼5x higher in HIR individuals with NAFLD compared to insulin-sensitive individuals without NAFLD, associated with ∼3x higher IRK T1160 phosphorylation, supporting the importance of PM sn-1,2 DAG-PKCe-IRK pT1160 pathway to mediate HIR in humans with NAFLD. In contrast there were no significant differences in ceramide content in any of the subcellular compartments. Conclusion: These data identify PM sn-1,2 DAGs as the key lipids that activate PKCe, and that hepatic PKCe is both necessary and sufficient in mediating HIR. Disclosure K. Lyu: None. D. Zhang: None. M. Kahn: None. M.R.S. Rodrigues: None. S. Hirabara: None. P. Luukkonen: None. S. Lee: None. S. Bhanot: None. J. Rinehart: None. N. Blume: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. M. Rasch: Employee; Self; Novo Nordisk A/S. Stock/Shareholder; Self; Novo Nordisk A/S. M.J. Serlie: None. J. Bogan: None. G. Cline: None. V. Samuel: None. G.I. Shulman: Advisory Panel; Self; AstraZeneca, Janssen Research \u0026 Development, LLC, Merck \u0026 Co., Inc. Advisory Panel; Spouse/Partner; Merck \u0026 Co., Inc. Consultant; Self; Novo Nordisk A/S. Consultant; Spouse/Partner; Novo Nordisk A/S. Other Relationship; Self; Gilead Sciences, Inc., iMetabolic Biopharma Corporation. Other Relationship; Spouse/Partner; iMetabolic Biopharma Corporation. Other Relationship; Self; Maze Therapeutics. Funding U.S. Public Health Service (R01DK116774, R01DK119968, R01DK113984, P30DK045735, R01 DK092661); U.S. Department of Veternas Affairs (I01BX000901)

Mechanism of Lipid-Induced White Adipose Tissue Insulin Resistance

Short-term Overnutrition Induces White Adipose Tissue Insulin Resistance Through Sn-1,2-diacylglycerol/pkcε/insulin Receptor Thr1160 Phosphorylation

Plasma Membrane sn-1,2 Diacylglycerol Mediates Lipid-Induced Hepatic Insulin Resistance

335-OR: Lipid-Induced Insulin Resistance in the Renal Cortex is Associated with Plasma Membrane Sn-1,2-diacylglycerol Accumulation and PKCe Translocation

Ectopic Lipid Deposition Mediates Insulin Resistance in Adipose Specific 11Β-Hydroxysteroid Dehydrogenase Type 1 Transgenic Mice.

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Membrane sn-1,2 Diacylglycerol Mediates Lipid-Induced Hepatic Insulin Resistance In Vivo

The Mechanisms by Which Adiponectin Reverses Insulin Resistance in High-Fat Diet Fed Mice

Insulin Receptor Thr1160 Phosphorylation Mediates Lipid-Induced Hepatic Insulin Resistance

Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes.

A Membrane-Bound Diacylglycerol Species Induces PKC-Mediated Hepatic Insulin Resistance

Role of Diacylglycerol Activation of PKCθ in Lipid-Induced Muscle Insulin Resistance in Humans

Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.

FFA-induced hepatic insulin resistance in vivo is mediated by PKCδ, NADPH oxidase, and oxidative stress

Hepatic Protein Kinase C-e Is Necessary and Sufficient in Mediating Lipid-Induced Hepatic Insulin Resistance

Hepatic Diacylglycerol-Associated Protein Kinase Cε Translocation Links Hepatic Steatosis to Hepatic Insulin Resistance in Humans.

Insulin And Insulin Signaling Play A Critical Role In Fat Induction Of Insulin Resistance In Mouse

Mechanism of Obesity-Related Lipotoxicity and Clinical Perspective

283-LB: Dissociating Insulin Signaling and SREBP1c Action from the Lipogenic Drive Seen in Human and Murine Hepatic Insulin Resistance

Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice

Adipocyte Inducible 6-Phosphofructo-2-kinase Suppresses Adipose Tissue Inflammation and Promotes Macrophage Anti-Inflammatory Activation